Collaborations & Alliances

Exelixis, Ipsen in Exclusive Cabozantinib Alliance

To further develop and commercialize Exelixis’ lead oncology drug

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Exelixis, Inc. and Ipsen have entered an exclusive licensing agreement for the further development and commercialization of cabozantinib, Exelixis’ lead oncology drug. Ipsen will have exclusive commercialization rights for current and future indications outside of the U.S., Canada and Japan. This agreement also includes rights to COMETRIQ, currently approved in the EU for progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). Exelixis will maintain exclusive co...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters